Scarica l'app Stockscreener
1.27
0.00%
0.00
Dopo l'orario di chiusura:
1.20
-0.07
-5.51%
Precedente Chiudi:
$1.27
Aprire:
$1.24
Volume 24 ore:
32,832
Relative Volume:
0.03
Capitalizzazione di mercato:
$3.32M
Reddito:
-
Utile/perdita netta:
$-16.28M
Rapporto P/E:
-0.0913
EPS:
-13.91
Flusso di cassa netto:
$-13.75M
1 W Prestazione:
-5.22%
1M Prestazione:
+17.59%
6M Prestazione:
-76.22%
1 anno Prestazione:
-85.49%
Intervallo 1D:
$1.20
$1.27
Intervallo di 1 settimana:
$1.13
$1.34
Portata 52W:
$0.95
$9.25
Pasithea Therapeutics Corp Stock (KTTA) Company Profile
Nome
Pasithea Therapeutics Corp
Settore
Industria
Telefono
(702) 514-4174
Indirizzo
1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH
Confronta KTTA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KTTA
Pasithea Therapeutics Corp
|
1.27 | 3.32M | 0 | -16.28M | -13.75M | -13.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 125.40B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 65.79B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 35.18B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 32.67B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 26.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Pasithea Therapeutics Corp Borsa (KTTA) Ultime notizie
Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference - The Manila Times
Pasithea Therapeutics to Present at 2025 CAGLA NeauxCancer Conference on Next-Generation MEK Inhibitor PAS-004 - Nasdaq
New Clinical Data: Pasithea's Novel Cancer Drug Shows Promise in Phase 1 Trial - Stock Titan
KTTA stock touches 52-week low at $1.12 amid market challenges - Investing.com India
KTTA stock touches 52-week low at $1.12 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $1.24 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $1.24 amid market challenges By Investing.com - Investing.com South Africa
Pasithea's PAS-004 advances in cancer trial with no toxicities - MSN
KTTA stock touches 52-week low at $1.32 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Update - Defense World
Pasithea Therapeutics Corp (KTTA) Stock: A Study of the Market Performance - The News Heater
An analyst sees good growth prospects for Pasithea Therapeutics Corp (KTTA) - SETE News
Daily Progress: Pasithea Therapeutics Corp (KTTA) Drop -21.90, Closing at 2.14 - The Dwinnex
Big Mid-Week Move From This Small Biotech - The Globe and Mail
KTTA stock touches 52-week low at $2.19 amid market challenges - MSN
Pasithea Therapeutics Corp (KTTA) Stock: Navigating Drops and Gains - The InvestChronicle
Understanding KTTA’s financial ratios: A beginner’s guide - US Post News
Pasithea (KTTA) Stock Spikes On Its Latest Clinical Trial Milestone - Stocks Telegraph
Pasithea Therapeutics Shares Rise After Positive Safety Review for Cancer Treatment - MarketWatch
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Top Premarket Gainers -February 05, 2025 at 07:47 am EST - Marketscreener.com
Pasithea announces Safety Review Committee recommendation - TipRanks
Pasithea's PAS-004 advances in cancer trial with no toxicities By Investing.com - Investing.com UK
Pasithea Therapeutics Announces Positive Safety Review - GlobeNewswire
Clinical Trial Breakthrough: Cancer Drug Shows Unprecedented Safety Profile in Phase 1 - StockTitan
US Stocks Mixed; Walt Disney Posts Upbeat Earnings - Benzinga
Pasithea Therapeutics Corp. (NASDAQ:KTTA) Short Interest Up 37.2% in December - Defense World
Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - GlobeNewswire
Pasithea Therapeutics Corp. Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4 - Marketscreener.com
KTTA stock touches 52-week low at $2.33 amid market challenges - Investing.com Australia
KTTA stock touches 52-week low at $2.33 amid market challenges By Investing.com - Investing.com South Africa
Analyzing Galecto (NASDAQ:GLTO) and Pasithea Therapeutics (NASDAQ:KTTA) - Defense World
Analyzing Pasithea Therapeutics (NASDAQ:KTTA) and MusclePharm (OTCMKTS:MSLP) - Defense World
KTTA stock touches 52-week low at $2.72 amid market challenges - Investing.com Nigeria
KTTA stock touches 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
KTTA stock touches 52-week low at $2.87 amid market challenges - Investing.com Nigeria
Pasithea Therapeutics Announces Positive Safety Review Committee Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer - Marketscreener.com
Pasithea Therapeutics Corp Azioni (KTTA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
10.70%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):